Condition: Cytomegalovirus Infection · Sponsor: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring valganciclovir treatment per investigator's judgment.
This description comes directly from the study's public registry record.
Pierre FRANGE, MD, PhD · +33 1.44.49.49.61 · pierre.frange@aphp.fr
Aminata TRAORE · +33 1.42.19.27.34 · aminata.traore@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Necker Enfants Malades | Paris, France | Recruiting |
| Hôpital de la Pitié Salpêtrière, Service de Néphrologie | Paris, Île-de-France Region, France | Recruiting |
| Hôpital Européen Georges Pompidou | Paris, Île-de-France Region, France | Recruiting |
| Hôpital Necker Enfants Malades - SMIT | Paris, Île-de-France Region, France | Recruiting |
| Centre 011-Hôpital Bichat, Service de Néphrologie | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06334497